Business Strategy Merck to Double R&D Productivity for Drugs
The German firm Merck has plans to double its R&D productivity with an aim to deliver transformative medicines in the fields of oncology, neurology and immunology. The move will help patients to get access to medicines faster.
Darmstadt/Germany – Merck recently shared updates on the company’s healthcare research and development strategy, aimed at doubling R&D productivity. To achieve the goal of introducing one new product or major indication every 1.5 years on average, the company will focus its expertise and capabilities and leverage synergies within the existing pipeline to deliver transformative medicines in oncology, neurology and immunology, augmented by an increased focus on external innovation.
The company expects to maintain the output of its internal discovery engine, while more than 50 % of future launches will result from external co-development partnerships and strategic in-licensing of assets for further in-house development. The strategy was shared at the company’s R&D Update Call.
“We are driven by our ambition to accelerate the discovery, development and delivery of innovative medicines to patients with cancer and neuroinflammatory and immune-mediated diseases,” said Danny Bar-Zohar, Global Head of Research & Development and Chief Medical Officer for the Healthcare business sector of Merck. “With a mindset of design simplicity and resource discipline paired with agility of execution, we will speed the generation of high-quality data that will support our efforts to bring forth more medicines for more patients, faster.”
To increase R&D productivity, the company will build on its established expertise in the underlying biology of its focused therapeutic areas of oncology, neurology and immunology and will leverage technological capabilities, particularly its industry-leading antibody-drug conjugate (ADC) technology.
Oncology: Synergistic Approaches to Striking Cancer at Its Core
The company’s oncology research and development strategy centers on cancer DNA while building on existing leadership in key cancer types, including head and neck, urothelial and colorectal cancers. The oncology pipeline is focused on synergistic approaches targeting key pathways involved in cancer cell survival, deploying mechanisms to hit cancer at its core:
- Delivering tumor DNA-damaging payloads right to the cancer with cutting-edge ADC technology
- Preventing cancer cells from repairing DNA damage, through inhibition of the DNA damage response (DDR)
- Restoring sensitivity to apoptosis, the cells’ natural death mechanism, which cancer can inhibit
The lead asset in the oncology pipeline is xevinapant, an investigational first-in-class potent oral small molecule IAP (Inhibitor of Apoptosis Protein) inhibitor being evaluated in the curative setting of locally advanced squamous cell carcinoma of the head and neck (LA Scchn) - an area that has not seen significant advances in treatment in the past 20 years.
The company’s broad portfolio of selective and potent DDR inhibitors includes several agents under development that directly inhibit DDR pathways required for cancer cell survival. By attacking the inherent genetic instability of cancer cells, these agents have the potential to exploit this weakness and tip the therapeutic balance in difficult-to-treat cancers. Earlier this year, M9140, the first ADC developed using the company’s own technology, advanced into human trials. The ongoing Phase Ia study is assessing M9140 in patients with colorectal cancer.
Neurology and Immunology: Expansion Building on Strength in Neurology and Immune Biology
In neurology and immunology, Merck aims to expand its Multiple Sclerosis (MS) portfolio with evobrutinib, an investigational, oral, CNS-penetrating, highly selective inhibitor of Bruton’s tyrosine kinase (BTK) with the potential to become a best-in-class treatment option for relapsing multiple sclerosis (RMS).
Merck also seeks to expand in neurology by evaluating the potential of oral cladribine in neurological diseases where inflammation is a primary driver, such as generalized myasthenia gravis.
The company is looking to diversify the pipeline with immunology and accelerate R&D by focusing on targets with proven biology via novel modalities. Key to these efforts is the ongoing Phase II Willow study of the TLR7/8 inhibitor enpatoran in cutaneous and systemic lupus erythematosus.
Building on expertise in neurology, the company is initiating a proof-of-concept study in neuromuscular conditions dermatomyositis and polymyositis with enpatoran in 2023. These conditions have a high unmet medical need characterized by progressive muscle weakness and show lupus-like patterns of immune activation and TLR7/8 expression.